immunoglobulin heavy constant muGenealiases: AGM1 · MU · VH
Q-omics provides the consensus-scored IGHM profile across patient tissues and cancer cell-line models. IGHM expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, IGHM is differentially expressed in 10, with the highest sampling consensus in LIHC. Additionally, IGHM RNA expression shows 14,400 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, LIHC, and GBM as cancer lineages where IGHM shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for IGHM — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes IGHM survival associations across molecular data types. IGHM RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible IGHM RNA expression–survival associations across cancer types. High IGHM expression shows favorable associations in HNSC, SKCM, CESC, LUAD, OV and LIHC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for IGHM RNA expression.
This table summarizes IGHM tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 7. The strongest signals are observed in LIHC for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for IGHM. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. IGHM shows lower tumor expression in LIHC, COAD and BRCA and higher tumor expression in LUAD, KIRC and HNSC. The LIHC box plot shows higher IGHM RNA expression in normal versus tumor tissue (log2 FC = −3.712, t-test p < 0.001).
This table shows molecular features associated with IGHM in patient tissues and cancer cell lines. In patient samples, IGHM shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, IGHM RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD.
